Trials / Completed
CompletedNCT01043887
Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)
A Single Dose Study to Investigate the Pharmacokinetics of Ridaforolimus in Patients With Hepatic Insufficiency
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the pharmacokinetics of ridaforolimus including the area under the concentration-time curve (AUC\[0-infinity\]) and maximum concentration (Cmax) after administration of a single dose of ridaforolimus in patients with moderate hepatic insufficiency and healthy matched control subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ridaforolimus | single oral dose administration 10 mg ridaforolimus |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2010-01-07
- Last updated
- 2015-04-29
Source: ClinicalTrials.gov record NCT01043887. Inclusion in this directory is not an endorsement.